Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30
- 678 Downloads
Neuroendocrine tumors (NETs) have proven to be appropriate neoplasms for peptide receptor radionuclide therapy (PRRT), as the majority of these slow-growing malignancies overexpress somatostatin receptors. The aim of this study was to evaluate changes in quality of life (QoL) of patients with P-NET following PRRT.
Sixty-eight patients with P-NET (31 female, mean age 61.4 y) underwent PRRT: 12 with NET of grade 1, 40 of grade 2, 8 of grade 3 (grade non-available n = 8). Prior to treatment, 39 patients showed ECOG 0, 26 patients ECOG 1, and three patients ECOG 2. Clinical assessment included evaluation of QoL and symptom changes using a standardized questionnaire (EORTC QLQ-C30) and was performed at baseline and every three months following each therapy cycle up to 12 months. Primary analysis compared QoL at baseline and after the fourth treatment cycle (N = 53).
Up to four treatment cycles PRRT were performed for each patient. The median cumulative administered activity was 28.2 GBq. Primary analysis revealed that compared to baseline QoL was significantly improved revealing increased global health status (p = 0.008) and social functioning (p = 0.049) at the end of the study. Furthermore, fatigue and appetite loss showed a significant improvement after the last PRRT cycle (fatigue: p = 0.029, appetite loss p = 0.015). Sub-analyses showed that QoL was improved revealing increased global health status (3 months after first, second, and third treatment cycle p = 0.048, p = 0.002, and p < 0.001, respectively), emotional functioning (3 months after first-third cycle p = 0.003, p = 0.049, and p = 0.001, respectively) and social functioning (3 months after the first and second p < 0.001, and after the third cycle p = 0.015, respectively). Furthermore, some symptoms were significantly alleviated compared with baseline: fatigue (after first-third cycle p = 0.026, p = 0.050, and p = 0.008, respectively), nausea and vomiting (after first and second cycle p = 0.006 and p = 0.001, respectively), dyspnea (after third cycle p = 0.025), appetite loss (after first-third cycle p = 0.010, p = 0.001, and p = 0.009, respectively), constipation (after first-third cycle p = 0.050, p = 0.003, and p = 0.060, respectively).
PRRT is an effective treatment of P-NET improving QoL of patients in terms of increasing global health and mitigation of physical complaints.
KeywordsPancreatic neuroendocrine tumor Peptide receptor radionuclide therapy Quality of life 177Lu-DOTATATE
The authors acknowledge Guido Lüchters who provided valuable support and advice in all statistical questions at any time.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no financial or non-financial competing interests.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 5.Ilan E, Sandstrom M, Wassberg C, Sundin A, Garske-Roman U, Eriksson B, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56:177–82. https://doi.org/10.2967/jnumed.114.148437.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62. https://doi.org/10.1200/JCO.2005.08.066.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:925–33. https://doi.org/10.1007/s00259-013-2677-3.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grunwald F, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55:183–90. https://doi.org/10.2967/jnumed.113.125336.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.van Vliet EI, van Eijck CH, de Krijger RR, Nieveen van Dijkum EJ, Teunissen JJ, Kam BL, et al. Neoadjuvant treatment of nonfunctioning pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate. J Nucl Med. 2015;56:1647–53. https://doi.org/10.2967/jnumed.115.158899.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Sabet A, Haslerud T, Pape UF, Ahmadzadehfar H, Grunwald F, Guhlke S, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:205–10. https://doi.org/10.1007/s00259-013-2547-z.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Ezziddin S, Sabet A, Heinemann F, Yong-Hing CJ, Ahmadzadehfar H, Guhlke S, et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J Nucl Med. 2011;52:1197–203. https://doi.org/10.2967/jnumed.111.090373.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Sabet A, Khalaf F, Yong-Hing CJ, Haslerud T, Ahmadzadehfar H, Guhlke S, et al. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. Nuklearmedizin. 2014;53:54–9. https://doi.org/10.3413/Nukmed-0614-13-08.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging. 2014;41:505–10. https://doi.org/10.1007/s00259-013-2601-x.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19. https://doi.org/10.1007/s00259-014-2893-5.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Procopio G, Ratta R, de Braud F. Improved quality of life is the way to longer life. wwwthelancetcom/oncology. 2016;17:862–3.Google Scholar
- 22.Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual (3rd edition). 2001.Google Scholar
- 23.Cameron AC, Pravin KT. Microeconometrics Using Stata Revised Edition. Stata Press. 2010.Google Scholar
- 24.Rabe-Hesketh S, Skrondal A. Multilevel and Longitudinal Modeling Using Stata. Stata Press, 3rd ed 2012;1–2.Google Scholar
- 25.Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O'Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16. https://doi.org/10.1007/s00259-012-2330-6.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Jimenez-Fonseca P, Carmona-Bayonas A, Martin-Perez E, Crespo G, Serrano R, Llanos M, et al. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2015;34:381–400. https://doi.org/10.1007/s10555-015-9573-1.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005;6:765–72. https://doi.org/10.1016/S1470-2045(05)70325-9.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev. 2013;39:610–21. https://doi.org/10.1016/j.ctrv.2012.12.014.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Land SR, Walcott FL, Liu Q, Wickerham DL, Costantino JP, Ganz PA. Symptoms and QOL as predictors of chemoprevention adherence in NRG oncology/NSABP trial P-1. J Natl Cancer Inst. 2016;108 https://doi.org/10.1093/jnci/djv365.
- 36.Luster M, Hanscheid H, Freudenberg LS, Verburg FA. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer. J Endocrinol Investig. 2012;35:21–9.Google Scholar
- 40.Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011;52:1361–8. https://doi.org/10.2967/jnumed.111.087932.CrossRefPubMedPubMedCentralGoogle Scholar